Intellia Therapeutics (NASDAQ:NTLA) Shares Up 11.8% – Time to Buy?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) rose 11.8% during mid-day trading on Monday . The company traded as high as $13.56 and last traded at $13.54. Approximately 2,720,228 shares changed hands during trading, a decline of 51% from the average daily volume of 5,497,521 shares. The stock had previously closed at $12.11.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on NTLA. Morgan Stanley raised their target price on Intellia Therapeutics from $11.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Monday, April 27th. Citizens Jmp reissued a “market outperform” rating and set a $30.00 target price on shares of Intellia Therapeutics in a research report on Monday. Bank of America reissued a “neutral” rating on shares of Intellia Therapeutics in a report on Monday, March 2nd. Chardan Capital boosted their target price on Intellia Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a report on Monday, April 27th. Finally, reissued a “buy” rating on shares of Intellia Therapeutics in a report on Tuesday, March 3rd. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $20.46.

Intellia Therapeutics Trading Up 13.5%

The company has a 50 day simple moving average of $13.60 and a 200 day simple moving average of $12.32. The stock has a market capitalization of $1.92 billion, a PE ratio of -3.87 and a beta of 1.92.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.11. The firm had revenue of $15.05 million during the quarter, compared to the consensus estimate of $13.81 million. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.During the same period in the prior year, the business earned ($1.10) EPS. On average, equities research analysts predict that Intellia Therapeutics, Inc. will post -3.18 EPS for the current year.

Institutional Trading of Intellia Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Comerica Bank lifted its position in Intellia Therapeutics by 45.8% in the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after purchasing an additional 901 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Intellia Therapeutics in the 2nd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Intellia Therapeutics in the 3rd quarter worth approximately $30,000. Advisory Services Network LLC purchased a new position in Intellia Therapeutics during the third quarter worth $33,000. Finally, Spire Wealth Management acquired a new position in shares of Intellia Therapeutics in the fourth quarter worth $37,000. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.